NCT07497555 Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial
| NCT ID | NCT07497555 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidad Autonoma de Nuevo Leon |
| Condition | Overweight (BMI > 25) |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-10-15 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate whether daily supplementation with cold-pressed pecan nut oil can reduce inflammation in adults with overweight. The main questions it aims to answer are: Does pecan nut oil supplementation reduce inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)? Does pecan nut oil supplementation improve biochemical parameters such as fasting blood glucose and lipid profile? Researchers will compare an experimental group receiving pecan nut oil to a control group with no intervention to determine its effect on inflammation and metabolic parameters. Participants will: Consume 30 g/day of cold-pressed pecan nut oil under fasting conditions for 8 weeks (experimental group) Maintain their usual diet and physical activity throughout the study Attend two evaluation visits (baseline and Day 60) for blood sample collection and anthropometric measurements Provide dietary information using a 24-hour dietary recall
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 65 years * Body mass index (BMI) ≥25 and \<30 kg/m² (overweight) * Willingness to participate and provide written informed consent * Ability to comply with study procedures and attend scheduled visits * Stable dietary habits and physical activity levels during the study period Exclusion Criteria: * Diagnosis of chronic diseases such as diabetes mellitus, cardiovascular disease, liver disease, renal disease, or autoimmune disorders * Use of anti-inflammatory medications, lipid-lowering drugs, or dietary supplements within the last 3 months * Smoking or excessive alcohol consumption * Pregnancy or lactation * Known allergy or intolerance to nuts or nut-derived products * Participation in another clinical trial within the last 3 months * Any condition that, in the investigator's opinion, may interfere with study participation or outcomes
Frequently Asked Questions
Who can join the NCT07497555 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Overweight (BMI > 25). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07497555 currently recruiting?
Yes, NCT07497555 is actively recruiting participants. Visit ClinicalTrials.gov or contact Universidad Autonoma de Nuevo Leon to inquire about joining.
Where is the NCT07497555 trial being conducted?
This trial is being conducted at Monterrey, Mexico.
Who is sponsoring the NCT07497555 clinical trial?
NCT07497555 is sponsored by Universidad Autonoma de Nuevo Leon. The trial plans to enroll 50 participants.